Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

Brentuximab Vedotin is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma

Robert Chen, Joycelynne M. Palmer, Ni-Chun Tsai, Sandra H. Thomas,Tanya Siddiqi, Leslie Popplewell, Len Farol, Auayporn Nademanee, Stephen J. Forman


We previously reported that brentuximab vedotin (BV) enabled successful reduced-intensity allogeneic hematopoietic cell transplantation (RIC-alloHCT) in patients with relapsed Hodgkin lymphoma, after a median follow-up of 14.4 months. We now provide an updated report on 21 patients who were treated from 2009 to 2012 with BV before RIC-alloHCT with a uniform fludarabine/melphalan conditioning regimen and donor source after a median follow-up of 29.9 months. We have also retrospectively compared the patient characteristics and outcomes of these BV-pretreated patients to 23 patients who received fludarabine/melphalan RIC-alloHCT without prior BV, in the time period before the drug was available (2003 to 2009). Patients who were treated with BV before RIC-alloHCT had a lower median hematopoietic cell transplantation–specific comorbidity index and a reduced number of peri-transplantation toxicities. There were also improvements in 2-year progression-free survival (59.3% versus 26.1%) and cumulative incidence of relapse/progression (23.8% versus 56.5%).

Biology of Blood and Marrow Transplantation
DOI: 10.1016/j.bbmt.2014.06.037


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Search this site

Search form